Literature DB >> 22449394

Psoriasiform pemphigus foliaceus: a report of two cases.

Sarah J Grekin1, Matthew C Fox, Johann E Gudjonsson, Douglas R Fullen.   

Abstract

Pemphigus foliaceus (PF) represents an autoimmune blistering disease characterized by the disruption of epidermal intercellular adhesion proteins. Clinical findings include superficial crusted erosions in a seborrheic distribution; however, the disease can rarely present as an exfoliative erythroderma. Histopathologic findings include acantholysis with cleavage within the granular layer. Direct immunofluorescence studies show intercellular IgG and complement deposition. We present two patients, to our dermatology department, with a previous diagnosis of psoriasis, with an exfoliative erythroderma, which ultimately proved to be because of PF based on histopathological features, direct immunofluorescence results and levels of antibodies against desmoglein 1. Both patients responded well to oral prednisone and rituximab. This variant of PF should be entertained in both the clinical differential diagnosis of psoriasiform erythroderma and in the microscopic differential diagnosis of psoriasiform epidermal hyperplasia with focal acantholysis, particularly in patients for whom the clinical history is not classic for psoriasis or for whom conventional psoriasis therapies have not proven beneficial.
Copyright © 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449394     DOI: 10.1111/j.1600-0560.2012.01866.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  2 in total

Review 1.  Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab.

Authors:  Francesco Caso; Luca Iaccarino; Silvano Bettio; Francesca Ometto; Luisa Costa; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 2.  Interaction of Psoriasis and Bullous Diseases.

Authors:  Teruki Dainichi; Kenji Kabashima
Journal:  Front Med (Lausanne)       Date:  2018-08-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.